Opioid Covalent Binding for Abuse Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid formulations are vulnerable to abuse due to their ability to be extracted and reused by skilled illicit chemists, despite efforts to create abuse-resistant versions.
Innovation Solution
Development of abuse-resistant opioid compounds where the opioid is covalently bound to a chemical moiety, creating a conditionally bioreversible derivative that remains inactive until oral administration, thereby reducing the potential for misuse.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioids are formulated in traditional forms, then they provide effective pain relief, but they are susceptible to extraction and abuse by illicit chemists
Solution Approach 1:
The opioid molecule is segmented by attaching it to a carrier molecule through a cleavable linker, creating a conditional prodrug system where the active opioid is separated from its delivery vehicle until activation occurs in the gastrointestinal tract
Solution Approach 2:
The chemical structure of the opioid is modified by covalent attachment to a carrier molecule, changing its physical and chemical parameters such as solubility, stability, and bioavailability, while maintaining its analgesic activity after activation
2Object-affected harmful factors
If abuse-resistant formulations are created, then extraction becomes more difficult, but skilled illicit chemists can still extract opioids from these formulations
Solution Approach 1:
A carrier molecule acts as an intermediary between the opioid and the body, requiring specific biological conditions (GI tract enzymes or pH) to activate the opioid, thereby preventing extraction and abuse while enabling therapeutic effect
Solution Approach 2:
The formulation uses a single-use, non-recoverable chemical structure where the carrier-opioid complex is designed to be activated and metabolized in the GI tract, preventing recovery and reuse by illicit chemists
3Object-affected harmful factors
If opioids are covalently bound to chemical moieties, then pharmacological activity and abuse potential decrease, but the compounds need to be activated through oral administration
Solution Approach 1:
The opioid is pre-modified with a carrier molecule and cleavable linker in a controlled manufacturing process, creating a stable prodrug that requires only simple oral administration for activation, rather than requiring complex activation procedures at the point of use
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The covalent binding of opioids to chemical moieties significantly decreases the pharmacological activity and abuse potential, making them less susceptible to extraction and reuse, effectively addressing the challenge of opioid abuse.
Implementation Method 1
an opioid covalently bound to a chemical moiety
Data Source
AI summary
Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.